title: Fertility outcomes of patients with early stage endometrial carcinoma.
abstract: OBJECTIVE
  Three to five percent of endometrial carcinoma patients are younger than 40 years and may desire fertility. Conservative treatment can be employed in these cases. We aimed to review treatment outcomes of patients who were diagnosed with endometrial carcinoma and who wanted to preserve their fertility.
  
  
  METHODS
  We reviewed nine patients who were diagnosed with early stage endometrial carcinoma and wanted to spare their fertility. The patients were followed up at Baskent University Adana Research Center from January 2004 to December 2011.
  
  
  RESULTS
  In all patients the carcinoma presented as polyps, which were resected by hysteroscopy. After being informed about both surgical and medical therapies, four patients preferred surgery and five preferred medical treatment. The mean number of in vitro fertilization trials after conservative treatment was 3.25. One woman, who was on medroxyprogesterone acetate, delivered a healthy term baby from a fresh cycle. Another woman, who was on dydrogesterone, got pregnant from a thawing cycle, which later ended up in a missed abortus. Of all the patients who chose medical treatment, three had surgery at the end. One woman developed an ovarian tumor during the follow-up; one woman had a recurrence of endometrial carcinoma on dilatation and curettage for missed abortus and one woman tried in vitro fertilization several times and could not get pregnant, thus decided to have surgery. Two women had stage IA endometrial carcinoma and one had stage IIB ovarian carcinoma.
  
  
  CONCLUSIONS
  Conservative treatment of endometrial carcinoma is safe in most cases. However, patients should be well-informed about the risks of conservative treatment because delaying definitive treatment sometimes worsens the prognosis.
authors.affiliation: Department of Obstetrics and Gynecology, Baskent University Faculty of Medicine, Ankara, Turkey.
authors.forename: Huriye Ayse
authors.initials: HA
authors.lastname: Parlakgumus
authors.forename: Esra Bulgan
authors.initials: EB
authors.lastname: Kilicdag
authors.forename: Erhan
authors.initials: E
authors.lastname: Simsek
authors.forename: Bulent
authors.initials: B
authors.lastname: Haydardedeoglu
authors.forename: Tayfun
authors.initials: T
authors.lastname: Cok
authors.forename: Pinar Caglar
authors.initials: PC
authors.lastname: Aytac
authors.forename: Tayfun
authors.initials: T
authors.lastname: Bagis
authors.forename: Serkan
authors.initials: S
authors.lastname: Erkanlı
mesh_terms: D000328:Adult; D002277:Carcinoma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D016889:Endometrial Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D005260:Female; D059247:Fertility Preservation / Q000009:adverse effects; D005307:Fertilization in Vitro; D005500:Follow-Up Studies; D006801:Humans; D015907:Hysteroscopy / Q000009:adverse effects; D007247:Infertility, Female / Q000139:chemically induced / Q000209:etiology / Q000628:therapy*; D009367:Neoplasm Staging; D059351:Organ Sparing Treatments / Q000009:adverse effects; D011127:Polyps / Q000473:pathology / Q000601:surgery; D057285:Precision Medicine; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D011256:Pregnancy Outcome; D012189:Retrospective Studies; D061665:Time-to-Treatment
keywords: conservative; endometrial carcinoma; fertility-preserving; medical; pregnancy